证券代码：002144 股票简称：宏达高科 公告编号：2025-008 宏达高科控股股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宏达高科控股股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 的第八届董事会第五次会议、第八届监事会第五次会议审议通过了《关于 20 24 年度利润分配预案的议案》，尚需提请公司 2024 年年度股东大会审议。 现将该方案的基本情况公告如下： 一、利润分配预案具体内容 根据天健会计师事务所（特殊普通合伙）出具的审计报告（天健审〔2025〕 7084 号），2024 年度公司实现归属于上市公司股东的净利润 27,944,496.63 元， 母公司实现净利润 32,795,332.96 元，按母公司净利润提取 10%的法定盈余公积 金 3,279,533.30 元后，加上年初母公司的未分配利润 879,239,237.06 元，因出售 海宁皮城部分股票增加未分配利润 50,208,379.25 元，再扣除本年度支付 2023 年 度现金股利 26,514,37 ...

内部控制审计报告 天健审〔2025〕7085 号 宏达高科控股股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了宏达高科控股股份有限公司（以下简称宏达高科公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是宏达 高科公司董事会的责任。 目 录 | 一、内部控制审计报告…………………………………………第 | | 1—2 | 页 | | --- | --- | --- | --- | | 二、本所营业执照复印件………………………………………… | 第 | 3 | 页 | | 三、本所执业证书复印件………………………………………… | 第 | 4 | 页 | | 四、本所从事证券服务业务备案完备证明材料………………… | 第 | 5 | 页 | | 五、本所签字注册会计师执业证书复印件………………… 第 | | 6—7 | 页 | 中国·杭州 中国注册会计师： 二〇二五年四月二十四日 二、注册 ...

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表…………第 3—3 页 非经营性资金占用及其他关联资金往来情况的 一、对报告使用者和使用目的的限定 本报告仅供宏达高科公司年度报告披露时使用，不得用作任何其他目的。我 们同意将本报告作为宏达高科公司年度报告的必备文件，随同其他文件一起报送 并对外披露。 为了更好地理解宏达高科公司 2024 年度非经营性资金占用及其他关联资金 往来情况，汇总表应当与已审的财务报表一并阅读。 二、管理层的责任 宏达高科公司管理层的责任是提供真实、合法、完整的相关资料，按照《上 市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会 公告〔2022〕26 号）和《深圳证券交易所上市公司自律监管指南第 1 号——业 务办理（2024 年修订）》（深证上〔2024〕397 号）的规定编制汇总表，并保证 其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 第 1 页 共 3 页 专项审计说明 天健审〔2025〕7086 号 宏达高科控 ...

目 录 | 一、审计报告……………………………………………………… 第 | 1—5 页 | | --- | --- | | 二、财务报表……………………………………………………… 第 | 6—13 页 | | （一）合并资产负债表…………………………………………… | 第 6 页 | | （二）母公司资产负债表………………………………………… | 第 7 页 | | （三）合并利润表………………………………………………… | 第 8 页 | | （四）母公司利润表……………………………………………… | 第 9 页 | | （五）合并现金流量表……………………………………………第 | 10 页 | | （六）母公司现金流量表…………………………………………第 | 11 页 | | （七）合并所有者权益变动表……………………………………第 | 12 页 | | （八）母公司所有者权益变动表…………………………………第 | 13 页 | | 三、财务报表附注…………………………………………………第 14—95 | 页 | | 四、本所营业执照复印件………………………………………………第 | 96 页 | | 五、 ...

Financial Performance - The company's operating revenue for 2024 was CNY 618,296,227.68, representing a 15.53% increase compared to CNY 535,183,326.15 in 2023[20]. - The net profit attributable to shareholders for 2024 decreased by 66.03% to CNY 27,944,496.63 from CNY 82,253,031.59 in 2023[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 13,980,118.51, down 80.84% from CNY 72,980,604.86 in the previous year[20]. - The net cash flow from operating activities increased by 43.52% to CNY 107,964,437.93 from CNY 75,228,177.61 in 2023[20]. - Basic earnings per share for 2024 were CNY 0.16, a decrease of 65.96% compared to CNY 0.47 in 2023[20]. - Total assets at the end of 2024 were CNY 2,246,858,404.52, reflecting a 3.52% increase from CNY 2,170,375,592.53 at the end of 2023[20]. - The net assets attributable to shareholders at the end of 2024 were CNY 2,034,300,674.44, up 1.92% from CNY 1,995,956,420.04 in 2023[20]. Revenue Segmentation - The fabric weaving segment generated revenue of 463.49 million yuan, up 19.78% year-on-year, while the medical device segment reported revenue of 61.39 million yuan, down 11.64% year-on-year[40]. - The fabric weaving segment generated ¥447,115,568.40, accounting for 72.31% of total revenue, with a year-on-year growth of 17.10%[43]. - The medical device segment's revenue was ¥62,799,573.50, with a gross margin of 55.93%, reflecting a year-on-year increase of 7.91%[44]. Market Trends and Industry Insights - The textile industry in China saw a 4% increase in revenue for large-scale enterprises in 2024, with a profit growth of 7.5%[30]. - The medical device market in China reached ¥1.35 trillion in 2024, growing approximately 6% year-on-year, driven by domestic demand and policy support[31]. - The automotive industry in China achieved production and sales of over 31 million vehicles in 2024, marking a year-on-year growth of 3.7% and 4.5% respectively[29]. - The utilization rate of the textile industry in China improved to 78.5% in 2024, reflecting a stable growth in production capacity[30]. Research and Development - The company has developed new products including the "AI Huiying" series of color ultrasound diagnostic devices and a smart massage robot, enhancing its product line in the medical device sector[36][40]. - The company holds over 120 patents related to ultrasound diagnosis and treatment, reflecting its commitment to research and development[38]. - The company completed several key R&D projects, including a high-elasticity fabric for bras and a low-melting-point recyclable TPU material, which are expected to positively impact market expansion[59]. - The introduction of AI algorithms in ultrasound technology is expected to enhance output control accuracy and safety, improving product competitiveness[60]. Cash Flow and Investment - Operating cash flow increased by 43.52% year-on-year, primarily due to a decrease in payments to suppliers[61]. - Net cash flow from investment activities decreased by 387.98% year-on-year, mainly due to the purchase of transferable bank certificates with a maturity of over one year[61]. - The company plans to invest ¥2 billion in an industrial upgrade project, with at least ¥1.5 billion allocated for fixed asset investment[42]. Governance and Compliance - The company has established a comprehensive governance structure to ensure compliance with regulatory requirements and effective decision-making[89]. - The board of directors consists of nine members, including three independent directors, ensuring adherence to governance standards[90]. - The company has implemented strict insider information management practices, ensuring confidentiality and compliance with regulations[92]. - The company has a clear asset ownership structure, with independent production systems and no violations regarding the use of funds or assets by the controlling shareholder[96]. Environmental Responsibility - The company has complied with environmental protection laws and standards, being classified as a key pollutant discharge unit[143]. - The total greenhouse gas emissions for 2024 amounted to 40,069.42 tons of CO2, with emissions from fuel combustion at 3,554.14 tons, electricity usage at 11,216.18 tons, and heat production at 25,299.1 tons[151]. - The company has a wastewater treatment capacity of 8,000 tons per day, with 4,000 tons discharged and 4,000 tons reused[147]. Employee and Talent Management - The company has established a competitive and fair salary policy, ensuring that employee compensation is based on performance, skills, and market levels[128]. - The company emphasizes talent development through a multi-level training program, including various training types such as safety production and professional skills enhancement[129]. - The professional composition includes 296 production personnel, 61 sales personnel, 147 technical personnel, 16 financial personnel, and 72 administrative personnel[127]. Future Outlook and Strategic Initiatives - The company plans to expand its market presence in Southeast Asia and the Middle East, with exports of domestic equipment growing over 20% year-on-year[32]. - The company aims to upgrade its industry through the "Hongda High-tech Industrialization Upgrade Project Investment Agreement" signed with local government[82]. - The company has set a performance guidance for the next fiscal year, aiming for a revenue increase of approximately 10%[103]. - The company is exploring potential acquisitions to diversify its product offerings, with a budget of 200 million yuan allocated for this purpose[111].

证券代码：002144 证券简称：宏达高科 公告编号：2025-004 宏达高科控股股份有限公司 关于签署土地使用权出让合同暨公司对外投资的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 宏达高科控股股份有限公司（以下简称"公司"）于2024年12月6日召开第 八届董事会第四次会议及第八届监事会第四次会议，于2024年12月23日召开2024 年第一次临时股东大会，分别审议通过了《关于拟签订投资协议暨对外投资的议 案》，同意公司与海宁市许村镇人民政府签署《宏达高科产业化升级项目投资协 议书》（以下简称"《投资协议书》"）。同时授权公司董事长及其指定的相关人 员全权办理与本次投资有关的全部事宜，包括但不限于：与政府有关部门签署和办理 投资建设相关的合同等事项，办理本次投资建设所需的监管机构、政府部门审批、备 案等相关事项。具体内容详见公司于巨潮资讯网披露的《关于公司签订投资协议 暨对外投资的公告》（公告编号：2024-032）。同月，公司与海宁市许村镇人 民政府举行签约仪式，共同签署完成了《投资协议书》。 近日，公司以3650万元人民币的价格竞得《投资 ...

证券代码：002144 证券简称：宏达高科 公告编号：2025-003 宏达高科控股股份有限公司 关于 2024 年度拟计提减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《深圳证券交易所股票上市规则》的相关规定，宏达高科控股股份有限公 司（以下简称"公司"）依据《企业会计准则》及公司相关会计政策的规定，将 公司本次拟计提减值准备的具体情况公告如下： 一、本次拟计提减值准备的情况概述 为真实反映公司的财务状况、资产价值及经营情况，本着谨慎性原则，根据《企 业会计准则》及公司会计政策的相关规定，公司对合并报表范围内截至2024年12月 31日的所属资产进行了减值测试，拟对可能发生减值损失的资产计提减值准备。 公司预计2024年全年计提资产和信用减值准备金额合计约为9,582.49万元， 本次计提减值准备情况未经会计师事务所审计。具体明细如下： 单位：万元 | 项目 | 本期拟计 提金额 | 情况说明 | | --- | --- | --- | | 信用减值损失 | 142.46 | 对应收款项以预期信用损失为基础确认损失准备 | | 存货减值 ...

Financial Performance Forecast - The estimated net profit attributable to shareholders for 2024 is projected to be between 22 million and 28 million yuan, representing a decline of approximately 65.96% to 73.25% compared to the previous year's profit of 82.253 million yuan [3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 17 million and 23 million yuan, reflecting a decrease of about 68.48% to 76.71% from the previous year's profit of 72.9804 million yuan [3]. - The basic earnings per share is forecasted to be between 0.1245 yuan and 0.1584 yuan, down from 0.4653 yuan in the same period last year [3]. - The performance forecast data is preliminary and has not been audited by the accounting firm, with detailed figures to be disclosed in the 2024 annual report [7]. - The company assures that the performance forecast will not affect normal business operations or listing status [7]. Business Operations - The company's main business in fabric weaving and medical devices is operating normally, with a revenue increase of approximately 20% in the automotive interior fabric and functional clothing fabric segments [6]. - Zhejiang Weirder Intelligent Medical Technology Co., Ltd. has obtained three medical device registration certificates and successfully developed an intelligent massage robot and the "AI Huiying" series of color ultrasound diagnostic equipment [6]. Asset Management - The company plans to recognize asset impairment provisions for long-term equity investments and goodwill arising from acquisitions, which will impact overall net profit [6].

，在执行产å"生命周期温室气体排放é‡çš"æ ¸æŸ¥ä¸- ，符å ˆISO14067:2018《温室气体产å"碳足迹é‡化的è¦求和指å —》的è¦æ± '，与商定的æ ¸æŸ¥èŒƒå›´ã€ç›®æ ‡å'Œå‡†åˆ™ä¸€è‡´ã€' å…¬å¸èŽ·å¾—ç¢³è¶³è¿¹æ ¸æŸ¥è®¤è¯的产å"为针织æœ 装é ¢æ– ™ï¼ˆé»'色）和针织æœ 装é ¢æ–™ï¼ˆä¸æµ…色）产å"，å–得的声明书编 å·åˆ†åˆ«ä¸ºCN24/00008253å'ŒCN24/00008254。 以上两项产å"的碳足迹认è¯ç»SGSæ ¸æŸ¥è®¡ç®— è´¢è"社1月10日电，å®达高科公告，近日，公å¸èŽ·å¾— 了通æ ‡æ ‡å‡†æŠ€æœ¯æœ 务有é™ å…¬å¸ï¼ˆSGSé¢å'两份产å"碳足迹æ ¸æŸ¥å£ °æ˜Žä¹¦ã€' ...

证券代码：002144 股票简称：宏达高科 公告编号：2024-035 宏达高科控股股份有限公司 关于公司签订投资协议暨对外投资的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、本次投资协议暨对外投资概述 1、协议各方签字盖章的《宏达高科产业化升级项目投资协议书》。 1 特此公告。 宏达高科控股股份有限公司董事会 二〇二四年十二月二十五日 为进一步适应公司业务发展需要，并提升核心竞争力，宏达高科控股股 份有限公司（以下简称"公司"）经第八届董事会四次会议及第八届监事会第 四次会议审议通过，提请 2024 年 12 月 23 日召开的公司 2024 年第一次临时 股东大会审议通过了《关于拟签订投资协议暨对外投资的议案》。本次对外投 资及协议具体情况详见公司公告（2024-032）。 二、本次投资协议暨对外投资的进展 近日，公司与海宁市许村镇人民政府举行签约仪式，共同签署了《宏达 高科产业化升级项目投资协议书》（以下简称"《协议书》"）。公司已收到由协 议各方签字盖章的《协议书》正本原件。《协议书》已由各方当事人签署完成。 三、后续事项及风险提示 公 ...